ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

SNGX Soligenix Inc

0.418
0.0135 (3.34%)
04 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Soligenix Inc SNGX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.0135 3.34% 0.418 08:59:38
개장가 저가 고가 종가 전일 종가
0.402 0.3958 0.4297 0.4045 0.4045
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202420:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/04/202421:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/04/202420:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/04/202420:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/04/202420:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/03/202420:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/02/202421:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/01/202421:30PRNUSSoligenix to Present at The Microcap Conference
08/01/202421:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/01/202421:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/01/202421:30PRNUSSoligenix Announces Publication Demonstrating Complete..
23/12/202306:05EDGAR2Form 8-K - Current report
18/12/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
16/12/202306:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202306:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202306:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202306:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202306:03EDGAR2Form 8-K - Current report
09/12/202307:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202307:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202307:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202307:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202306:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202321:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202321:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
18/11/202306:05EDGAR2Form 8-K - Current report
18/11/202306:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
14/11/202306:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202321:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
21/10/202305:05EDGAR2Form 8-K - Current report
21/10/202305:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
18/10/202302:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/10/202302:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202305:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202320:30PRNUSSoligenix to Present at The ThinkEquity Conference
14/10/202302:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/09/202320:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
23/09/202305:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
23/09/202305:05EDGAR2Form 8-K - Current report
23/09/202305:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
16/09/202305:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/09/202305:05EDGAR2Form 8-K - Current report
31/08/202305:05EDGAR2Form S-3 - Registration statement under Securities Act of..
22/08/202306:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/08/202320:30PRNUSSoligenix Announces Recent Accomplishments And Second..
15/08/202305:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
10/08/202320:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
08/08/202305:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/08/202305:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/07/202320:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..

최근 히스토리

Delayed Upgrade Clock